Biogen Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher A. Viehbacher
- Full Time Employees
- 7,605
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 225 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Sep 17, 1991
- CIK
- 0000875045
- Website
- biogen.com
- Similar Companies
- Business
- Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.
Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping List
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Biogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their Rights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position